On 19 October 1943, researchers at Rutgers University in New Jersey isolated streptomycin, an antibiotic that would transform the treatment of tuberculosis and mark a major milestone in modern medicine.
The streptomycin discovery offered new hope against a disease that had killed millions of people worldwide and for which effective drug treatments had previously been unavailable.
A breakthrough in the fight against tuberculosis
Tuberculosis, commonly known as TB, is a bacterial infection that most often affects the lungs. Before the development of effective antibiotics, treatment largely depended on rest, nutrition and prolonged stays in sanatoriums.
The disease was frequently fatal, and even those who survived could experience lasting damage to their health.
Streptomycin was isolated from a soil-dwelling bacterium, Streptomyces griseus, during research at Rutgers University led by microbiologist Selman Waksman.
Graduate student Albert Schatz played a central role in isolating the antibiotic, working alongside Elizabeth Bugie, who contributed to the early research.
The discovery was particularly significant because streptomycin proved effective against Mycobacterium tuberculosis, the bacterium responsible for TB.
From laboratory discovery to lifesaving treatment
The identification of streptomycin in 1943 was only the beginning. Researchers still needed to establish whether the antibiotic could be used safely and effectively in patients.
Clinical trials in the following years demonstrated its potential to treat tuberculosis, opening the way for a new era of antibiotic therapy.
Streptomycin also helped establish the importance of combining different medicines in TB treatment. When used alone, the antibiotic could lead to drug resistance, making it less effective over time.
As other anti-tuberculosis medicines became available, combination treatment improved outcomes and reduced the risk of resistant infections.
Recognition and controversy
The streptomycin discovery brought international recognition to Rutgers University’s research programme.
In 1952, Selman Waksman received the Nobel Prize in Physiology or Medicine for the discovery of streptomycin, although the award also became part of a longstanding dispute over recognition of Albert Schatz’s contribution.
Schatz had carried out the laboratory work that led to the antibiotic’s isolation, while Bugie’s role in the research was also historically significant.
The controversy highlighted questions about scientific credit and the contributions of junior researchers to major medical discoveries.
A lasting legacy in modern medicine
More than eight decades later, tuberculosis remains a serious global health challenge, particularly in countries where access to diagnosis and treatment is limited.
Although streptomycin is no longer a routine first-choice treatment for most cases of tuberculosis, its discovery helped lay the foundations for the antibiotic combinations used to treat the disease today.
The events of 19 October 1943 remain an important chapter in medical history, demonstrating how research into microorganisms found in ordinary soil could lead to treatments that saved countless lives.
Also Read: icosia A&E department reopens after €4.1 million government investment
For more videos and updates, check out our YouTube channel
